AR and SMARCA2 |
androgen receptor |
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 |
- Generic Transcription Pathway
- Nuclear Receptor transcription pathway
|
- Chromatin modifying enzymes
- Chromatin organization
- RMTs methylate histone arginines
|
- Levonorgestrel
- Spironolactone
- Flutamide
- Oxandrolone
- Testosterone
- Nilutamide
- Fludrocortisone
- Drostanolone
- Nandrolone phenpropionate
- Bicalutamide
- Fluoxymesterone
- Drospirenone
- Danazol
- Testosterone Propionate
- Delta1-dihydrotestosterone
- Boldenone
- Calusterone
- Flufenamic Acid
- Dihydrotestosterone
- (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide
- Methyltrienolone
- (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE
- Cyproterone
- Methyltestosterone
- 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE
- (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
- 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE
- (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide
- 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile
- (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide
- (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
- (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE
- S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE
- 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE
- 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile
- 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE
- 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL
- Nandrolone decanoate
- Enzalutamide
|
|
|
|
NR3C1 and NFKB1 |
nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) |
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 |
- BMAL1:CLOCK,NPAS2 activates circadian gene expression
|
- Signaling by the B Cell Receptor (BCR)
- NF-kB is activated and signals survival
- Downstream TCR signaling
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- Cellular Senescence
- RIP-mediated NFkB activation via ZBP1
- Toll Like Receptor TLR6:TLR2 Cascade
- DEx/H-box helicases activate type I IFN and inflammatory cytokines production
- Activated TLR4 signalling
- Toll Like Receptor TLR1:TLR2 Cascade
- Downstream signaling events of B Cell Receptor (BCR)
- FCERI mediated NF-kB activation
- MyD88 cascade initiated on plasma membrane
- Toll Like Receptor 5 (TLR5) Cascade
- ZBP1(DAI) mediated induction of type I IFNs
- p75NTR signals via NF-kB
- Transcriptional regulation of white adipocyte differentiation
- MyD88 dependent cascade initiated on endosome
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- MyD88:Mal cascade initiated on plasma membrane
- Toll Like Receptor 9 (TLR9) Cascade
- Innate Immune System
- Regulated proteolysis of p75NTR
- Signalling by NGF
- TRIF-mediated TLR3/TLR4 signaling
- Cytosolic sensors of pathogen-associated DNA
- Senescence-Associated Secretory Phenotype (SASP)
- Cytokine Signaling in Immune system
- p75 NTR receptor-mediated signalling
- MyD88-independent cascade
- Toll Like Receptor 2 (TLR2) Cascade
- RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
- Signaling by Interleukins
- TCR signaling
- Toll-Like Receptors Cascades
- Toll Like Receptor 10 (TLR10) Cascade
- Interleukin-1 processing
- Toll Like Receptor 3 (TLR3) Cascade
- Toll Like Receptor 4 (TLR4) Cascade
- Activation of NF-kappaB in B cells
- Fc epsilon receptor (FCERI) signaling
- TRAF6 mediated NF-kB activation
- Interleukin-1 signaling
- Adaptive Immune System
- TAK1 activates NFkB by phosphorylation and activation of IKKs complex
|
- Flunisolide
- Diflorasone
- Alclometasone
- Medrysone
- Amcinonide
- Fluorometholone
- Megestrol
- Beclometasone dipropionate
- Betamethasone
- Desoximetasone
- Fluticasone Propionate
- Fluocinolone Acetonide
- Halobetasol Propionate
- Triamcinolone
- Prednisone
- Flumethasone Pivalate
- Fludrocortisone
- Hydrocortisone
- Mometasone
- Hydrocortamate
- Mifepristone
- Clocortolone
- Flurandrenolide
- Prednisolone
- Loteprednol
- Rimexolone
- Methylprednisolone
- Clobetasol
- Fluocinonide
- Prednicarbate
- Fluoxymesterone
- Budesonide
- Dexamethasone
- Desonide
- Cortisone acetate
- Paramethasone
- Ciclesonide
- Hexane-1,6-Diol
- Difluprednate
- Fluticasone furoate
|
- Thalidomide
- Pranlukast
- Triflusal
|
|
|
NR3C1 and DCAF6 |
nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) |
DDB1 and CUL4 associated factor 6 |
- BMAL1:CLOCK,NPAS2 activates circadian gene expression
|
|
- Flunisolide
- Diflorasone
- Alclometasone
- Medrysone
- Amcinonide
- Fluorometholone
- Megestrol
- Beclometasone dipropionate
- Betamethasone
- Desoximetasone
- Fluticasone Propionate
- Fluocinolone Acetonide
- Halobetasol Propionate
- Triamcinolone
- Prednisone
- Flumethasone Pivalate
- Fludrocortisone
- Hydrocortisone
- Mometasone
- Hydrocortamate
- Mifepristone
- Clocortolone
- Flurandrenolide
- Prednisolone
- Loteprednol
- Rimexolone
- Methylprednisolone
- Clobetasol
- Fluocinonide
- Prednicarbate
- Fluoxymesterone
- Budesonide
- Dexamethasone
- Desonide
- Cortisone acetate
- Paramethasone
- Ciclesonide
- Hexane-1,6-Diol
- Difluprednate
- Fluticasone furoate
|
|
|
|
NR3C1 and SMARCA2 |
nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) |
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 |
- BMAL1:CLOCK,NPAS2 activates circadian gene expression
|
- Chromatin modifying enzymes
- Chromatin organization
- RMTs methylate histone arginines
|
- Flunisolide
- Diflorasone
- Alclometasone
- Medrysone
- Amcinonide
- Fluorometholone
- Megestrol
- Beclometasone dipropionate
- Betamethasone
- Desoximetasone
- Fluticasone Propionate
- Fluocinolone Acetonide
- Halobetasol Propionate
- Triamcinolone
- Prednisone
- Flumethasone Pivalate
- Fludrocortisone
- Hydrocortisone
- Mometasone
- Hydrocortamate
- Mifepristone
- Clocortolone
- Flurandrenolide
- Prednisolone
- Loteprednol
- Rimexolone
- Methylprednisolone
- Clobetasol
- Fluocinonide
- Prednicarbate
- Fluoxymesterone
- Budesonide
- Dexamethasone
- Desonide
- Cortisone acetate
- Paramethasone
- Ciclesonide
- Hexane-1,6-Diol
- Difluprednate
- Fluticasone furoate
|
|
|
|
PPARG and NFKB1 |
peroxisome proliferator-activated receptor gamma |
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 |
- PPARA activates gene expression
- Fatty acid, triacylglycerol, and ketone body metabolism
- Metabolism of lipids and lipoproteins
- Generic Transcription Pathway
- Transcriptional regulation of white adipocyte differentiation
- Nuclear Receptor transcription pathway
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
|
- Signaling by the B Cell Receptor (BCR)
- NF-kB is activated and signals survival
- Downstream TCR signaling
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- Cellular Senescence
- RIP-mediated NFkB activation via ZBP1
- Toll Like Receptor TLR6:TLR2 Cascade
- DEx/H-box helicases activate type I IFN and inflammatory cytokines production
- Activated TLR4 signalling
- Toll Like Receptor TLR1:TLR2 Cascade
- Downstream signaling events of B Cell Receptor (BCR)
- FCERI mediated NF-kB activation
- MyD88 cascade initiated on plasma membrane
- Toll Like Receptor 5 (TLR5) Cascade
- ZBP1(DAI) mediated induction of type I IFNs
- p75NTR signals via NF-kB
- Transcriptional regulation of white adipocyte differentiation
- MyD88 dependent cascade initiated on endosome
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- MyD88:Mal cascade initiated on plasma membrane
- Toll Like Receptor 9 (TLR9) Cascade
- Innate Immune System
- Regulated proteolysis of p75NTR
- Signalling by NGF
- TRIF-mediated TLR3/TLR4 signaling
- Cytosolic sensors of pathogen-associated DNA
- Senescence-Associated Secretory Phenotype (SASP)
- Cytokine Signaling in Immune system
- p75 NTR receptor-mediated signalling
- MyD88-independent cascade
- Toll Like Receptor 2 (TLR2) Cascade
- RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
- Signaling by Interleukins
- TCR signaling
- Toll-Like Receptors Cascades
- Toll Like Receptor 10 (TLR10) Cascade
- Interleukin-1 processing
- Toll Like Receptor 3 (TLR3) Cascade
- Toll Like Receptor 4 (TLR4) Cascade
- Activation of NF-kappaB in B cells
- Fc epsilon receptor (FCERI) signaling
- TRAF6 mediated NF-kB activation
- Interleukin-1 signaling
- Adaptive Immune System
- TAK1 activates NFkB by phosphorylation and activation of IKKs complex
|
- Icosapent
- Troglitazone
- Mesalazine
- Indomethacin
- Rosiglitazone
- Nateglinide
- Sulfasalazine
- Repaglinide
- Telmisartan
- Balsalazide
- Ibuprofen
- Glipizide
- Pioglitazone
- Mitiglinide
- Bezafibrate
- (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid
- 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
- (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
- 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid
- (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid
- (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid
- (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid
- (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid
- difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron
- (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID
- 3-(5-methoxy-1H-indol-3-yl)propanoic acid
- 3-{5-methoxy-1-[(4-methoxyphenyl)sulfonyl]-1H-indol-3-yl}propanoic acid
- (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
- 2-chloro-5-nitro-N-phenylbenzamide
- (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid
- 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid
- 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
- (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid
- 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE
- (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
- ALEGLITAZAR
|
- Thalidomide
- Pranlukast
- Triflusal
|
|
|
PPARG and HDAC4 |
peroxisome proliferator-activated receptor gamma |
histone deacetylase 4 |
- PPARA activates gene expression
- Fatty acid, triacylglycerol, and ketone body metabolism
- Metabolism of lipids and lipoproteins
- Generic Transcription Pathway
- Transcriptional regulation of white adipocyte differentiation
- Nuclear Receptor transcription pathway
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
|
- Signaling by NOTCH1 HD Domain Mutants in Cancer
- Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
- Signaling by NOTCH
- Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
- NOTCH1 Intracellular Domain Regulates Transcription
- Signaling by NOTCH1
- Signaling by NOTCH1 PEST Domain Mutants in Cancer
- Signaling by NOTCH1 in Cancer
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- FBXW7 Mutants and NOTCH1 in Cancer
|
- Icosapent
- Troglitazone
- Mesalazine
- Indomethacin
- Rosiglitazone
- Nateglinide
- Sulfasalazine
- Repaglinide
- Telmisartan
- Balsalazide
- Ibuprofen
- Glipizide
- Pioglitazone
- Mitiglinide
- Bezafibrate
- (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid
- 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
- (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
- 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid
- (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid
- (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid
- (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid
- (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid
- difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron
- (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID
- 3-(5-methoxy-1H-indol-3-yl)propanoic acid
- 3-{5-methoxy-1-[(4-methoxyphenyl)sulfonyl]-1H-indol-3-yl}propanoic acid
- (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
- 2-chloro-5-nitro-N-phenylbenzamide
- (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid
- 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid
- 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
- (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid
- 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE
- (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
- ALEGLITAZAR
|
|
|
|
PDE4B and DISC1 |
phosphodiesterase 4B, cAMP-specific |
disrupted in schizophrenia 1 |
- Signaling by GPCR
- GPCR downstream signaling
- G alpha (s) signalling events
- Opioid Signalling
- DARPP-32 events
|
|
- Adenosine monophosphate
- Caffeine
- Theophylline
- Dyphylline
- Pentoxifylline
- Enprofylline
- Ketotifen
- Iloprost
- Papaverine
- Theobromine
- Amrinone
- (R)-Mesopram
- Roflumilast
- Piclamilast
- 4-[3-(Cyclopentyloxy)-4-Methoxyphenyl]-2-Pyrrolidinone
- 3,5-Dimethyl-1-(3-Nitrophenyl)-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester
- Filaminast
- 8-Bromo-Adenosine-5\'-Monophosphate
- (S)-Rolipram
- 1-(2-Chlorophenyl)-3,5-Dimethyl-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester
- Cis-4-Cyano-4-[3-(Cyclopentyloxy)-4-Methoxyphenyl]Cyclohexanecarboxylic Acid
- (R)-Rolipram
- S,S-(2-Hydroxyethyl)Thiocysteine
- Ibudilast
- 1-ethyl-N-(phenylmethyl)-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
- 4-[8-(3-nitrophenyl)-1,7-naphthyridin-6-yl]benzoic acid
|
|
|
|
CSNK2A1 and GABRR1 |
casein kinase 2, alpha 1 polypeptide |
gamma-aminobutyric acid (GABA) A receptor, rho 1 |
- Mitotic Prometaphase
- Signal transduction by L1
- Axon guidance
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- L1CAM interactions
- Signaling by Wnt
- Cell Cycle, Mitotic
- M Phase
- WNT mediated activation of DVL
- TCF dependent signaling in response to WNT
- RNF mutants show enhanced WNT signaling and proliferation
- XAV939 inhibits tankyrase, stabilizing AXIN
- Signaling by WNT in cancer
- Condensation of Prometaphase Chromosomes
|
- GABA receptor activation
- GABA A (rho) receptor activation
- Ion channel transport
- Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
- Ligand-gated ion channel transport
- Transmission across Chemical Synapses
|
- (5-Oxo-5,6-Dihydro-Indolo[1,2-a]Quinazolin-7-Yl)-Acetic Acid
- 1,8-Di-Hydroxy-4-Nitro-Xanthen-9-One
- Resveratrol
- 1,8-Di-Hydroxy-4-Nitro-Anthraquinone
- Benzamidine
- 5,8-Di-Amino-1,4-Dihydroxy-Anthraquinone
- Phosphoaminophosphonic Acid-Adenylate Ester
- Tetrabromo-2-Benzotriazole
- DIMETHYL-(4,5,6,7-TETRABROMO-1H-BENZOIMIDAZOL-2-YL)-AMINE
- S-METHYL-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
- N1,N2-ETHYLENE-2-METHYLAMINO-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
- 3-METHYL-1,6,8-TRIHYDROXYANTHRAQUINONE
- 3,8-DIBROMO-7-HYDROXY-4-METHYL-2H-CHROMEN-2-ONE
- 19-(cyclopropylamino)-4,6,7,15-tetrahydro-5H-16,1-(azenometheno)-10,14-(metheno)pyrazolo[4,3-o][1,3,9]triazacyclohexadecin-8(9H)-one
- N,N\'-DIPHENYLPYRAZOLO[1,5-A][1,3,5]TRIAZINE-2,4-DIAMINE
- 4-(2-(1H-IMIDAZOL-4-YL)ETHYLAMINO)-2-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
- 2-(CYCLOHEXYLMETHYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
- 2-(4-CHLOROBENZYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
- 2-(4-ETHYLPIPERAZIN-1-YL)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
- N-(3-(8-CYANO-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZIN-2-YLAMINO)PHENYL)ACETAMIDE
- 2,3,7,8-tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione
- 5,6-dichloro-1-beta-D-ribofuranosyl-1H-benzimidazole
- 1,2,5,8-tetrahydroxyanthracene-9,10-dione
- Ellagic Acid
|
- Lorazepam
- Temazepam
- Clobazam
- Alprazolam
- Picrotoxin
- Chlordiazepoxide
- Adinazolam
- Clorazepate
- Midazolam
- Flurazepam
- Halazepam
- Diazepam
- Oxazepam
- Triazolam
- Clonazepam
- Estazolam
- Bromazepam
- Clotiazepam
- Fludiazepam
- Prazepam
- Quazepam
- Cinolazepam
- Nitrazepam
|
|
|
CALM3 and TCF4 |
calmodulin 3 (phosphorylase kinase, delta) |
transcription factor 4 |
- Signaling by the B Cell Receptor (BCR)
- Signaling by GPCR
- Ca-dependent events
- CaM pathway
- Signaling by FGFR in disease
- Phospholipase C-mediated cascade
- Signaling by Wnt
- Platelet degranulation
- Signaling by EGFRvIII in Cancer
- CREB phosphorylation through the activation of Ras
- PLCG1 events in ERBB2 signaling
- Glucose metabolism
- DAP12 signaling
- Synthesis of IP3 and IP4 in the cytosol
- Myoclonic epilepsy of Lafora
- Response to elevated platelet cytosolic Ca2+
- Glycogen storage diseases
- Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
- Activation of Ca-permeable Kainate Receptor
- Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
- Ionotropic activity of Kainate Receptors
- Signaling by PDGF
- Calmodulin induced events
- CaMK IV-mediated phosphorylation of CREB
- DAP12 interactions
- Glycogen breakdown (glycogenolysis)
- Opioid Signalling
- Activation of Kainate Receptors upon glutamate binding
- Diseases associated with visual transduction
- Inositol phosphate metabolism
- EGFR interacts with phospholipase C-gamma
- CaMK IV-mediated phosphorylation of CREB
- Signaling by ERBB2
- Signaling by EGFR
- Signaling by VEGF
- CREB phosphorylation through the activation of CaMKK
- Downstream signal transduction
- Calmodulin induced events
- CREB phosphorylation through the activation of CaMKII
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- Transcriptional activation of mitochondrial biogenesis
- Metabolism of carbohydrates
- Platelet activation, signaling and aggregation
- Adaptive Immune System
- Transmission across Chemical Synapses
- Ras activation uopn Ca2+ infux through NMDA receptor
- Organelle biogenesis and maintenance
- Cam-PDE 1 activation
- Translocation of GLUT4 to the plasma membrane
- VEGFA-VEGFR2 Pathway
- DAG and IP3 signaling
- CaM pathway
- Inactivation, recovery and regulation of the phototransduction cascade
- Metabolism of nitric oxide
- VEGFR2 mediated cell proliferation
- VEGFR2 mediated vascular permeability
- Activation of NMDA receptor upon glutamate binding and postsynaptic events
- The phototransduction cascade
- Downstream signaling of activated FGFR
- DARPP-32 events
- eNOS activation and regulation
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Innate Immune System
- Post NMDA receptor activation events
- Signalling by NGF
- PLC beta mediated events
- Smooth Muscle Contraction
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- G-protein mediated events
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Mitochondrial biogenesis
- beta-catenin independent WNT signaling
- Signaling by FGFR
- eNOS activation
- Cam-PDE 1 activation
- Ca2+ pathway
- Visual phototransduction
- Activation of CaMK IV
- PLC-gamma1 signalling
- FCERI mediated Ca+2 mobilization
|
- CDO in myogenesis
- Myogenesis
|
- Dibucaine
- Nicardipine
- Fluphenazine
- Isoflurane
- Trifluoperazine
- Loperamide
- Perphenazine
- Phenoxybenzamine
- Felodipine
- Melatonin
- Promethazine
- Pimozide
- Nifedipine
- Bepridil
- Calcium
- Aprindine
- 3\'\'-(Beta-Chloroethyl)-2\'\',4\'\'-Dioxo-3, 5\'\'-Spiro-Oxazolidino-4-Deacetoxy-Vinblastine
- 2-Methyl-2-Propanol
- N-Trimethyllysine
- N-(6-Aminohexyl)-5-Chloro-1-Naphthalenesulfonamide
- Prenylamine
- Flunarizine
- (3Z)-N,N-DIMETHYL-2-OXO-3-(4,5,6,7-TETRAHYDRO-1H-INDOL-2-YLMETHYLIDENE)-2,3-DIHYDRO-1H-INDOLE-5-SULFONAMIDE
- MYRISTIC ACID
|
|
|
|
CSNK2A1 and CTDP1 |
casein kinase 2, alpha 1 polypeptide |
CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) phosphatase, subunit 1 |
- Mitotic Prometaphase
- Signal transduction by L1
- Axon guidance
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- L1CAM interactions
- Signaling by Wnt
- Cell Cycle, Mitotic
- M Phase
- WNT mediated activation of DVL
- TCF dependent signaling in response to WNT
- RNF mutants show enhanced WNT signaling and proliferation
- XAV939 inhibits tankyrase, stabilizing AXIN
- Signaling by WNT in cancer
- Condensation of Prometaphase Chromosomes
|
- Formation of HIV-1 elongation complex containing HIV-1 Tat
- RNA Polymerase II Transcription
- Abortive elongation of HIV-1 transcript in the absence of Tat
- HIV Infection
- Formation of the Early Elongation Complex
- Tat-mediated elongation of the HIV-1 transcript
- Tat-mediated HIV elongation arrest and recovery
- RNA Polymerase II Pre-transcription Events
- Late Phase of HIV Life Cycle
- Pausing and recovery of Tat-mediated HIV elongation
- Formation of RNA Pol II elongation complex
- HIV elongation arrest and recovery
- HIV Life Cycle
- Pausing and recovery of HIV elongation
- Formation of HIV elongation complex in the absence of HIV Tat
- Formation of the HIV-1 Early Elongation Complex
- HIV Transcription Elongation
- Transcription of the HIV genome
- RNA Polymerase II Transcription Elongation
|
- (5-Oxo-5,6-Dihydro-Indolo[1,2-a]Quinazolin-7-Yl)-Acetic Acid
- 1,8-Di-Hydroxy-4-Nitro-Xanthen-9-One
- Resveratrol
- 1,8-Di-Hydroxy-4-Nitro-Anthraquinone
- Benzamidine
- 5,8-Di-Amino-1,4-Dihydroxy-Anthraquinone
- Phosphoaminophosphonic Acid-Adenylate Ester
- Tetrabromo-2-Benzotriazole
- DIMETHYL-(4,5,6,7-TETRABROMO-1H-BENZOIMIDAZOL-2-YL)-AMINE
- S-METHYL-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
- N1,N2-ETHYLENE-2-METHYLAMINO-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
- 3-METHYL-1,6,8-TRIHYDROXYANTHRAQUINONE
- 3,8-DIBROMO-7-HYDROXY-4-METHYL-2H-CHROMEN-2-ONE
- 19-(cyclopropylamino)-4,6,7,15-tetrahydro-5H-16,1-(azenometheno)-10,14-(metheno)pyrazolo[4,3-o][1,3,9]triazacyclohexadecin-8(9H)-one
- N,N\'-DIPHENYLPYRAZOLO[1,5-A][1,3,5]TRIAZINE-2,4-DIAMINE
- 4-(2-(1H-IMIDAZOL-4-YL)ETHYLAMINO)-2-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
- 2-(CYCLOHEXYLMETHYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
- 2-(4-CHLOROBENZYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
- 2-(4-ETHYLPIPERAZIN-1-YL)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
- N-(3-(8-CYANO-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZIN-2-YLAMINO)PHENYL)ACETAMIDE
- 2,3,7,8-tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione
- 5,6-dichloro-1-beta-D-ribofuranosyl-1H-benzimidazole
- 1,2,5,8-tetrahydroxyanthracene-9,10-dione
- Ellagic Acid
|
|
|
|
CSNK2A1 and KIF5C |
casein kinase 2, alpha 1 polypeptide |
kinesin family member 5C |
- Mitotic Prometaphase
- Signal transduction by L1
- Axon guidance
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- L1CAM interactions
- Signaling by Wnt
- Cell Cycle, Mitotic
- M Phase
- WNT mediated activation of DVL
- TCF dependent signaling in response to WNT
- RNF mutants show enhanced WNT signaling and proliferation
- XAV939 inhibits tankyrase, stabilizing AXIN
- Signaling by WNT in cancer
- Condensation of Prometaphase Chromosomes
|
- Peptide hormone metabolism
- Insulin processing
|
- (5-Oxo-5,6-Dihydro-Indolo[1,2-a]Quinazolin-7-Yl)-Acetic Acid
- 1,8-Di-Hydroxy-4-Nitro-Xanthen-9-One
- Resveratrol
- 1,8-Di-Hydroxy-4-Nitro-Anthraquinone
- Benzamidine
- 5,8-Di-Amino-1,4-Dihydroxy-Anthraquinone
- Phosphoaminophosphonic Acid-Adenylate Ester
- Tetrabromo-2-Benzotriazole
- DIMETHYL-(4,5,6,7-TETRABROMO-1H-BENZOIMIDAZOL-2-YL)-AMINE
- S-METHYL-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
- N1,N2-ETHYLENE-2-METHYLAMINO-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
- 3-METHYL-1,6,8-TRIHYDROXYANTHRAQUINONE
- 3,8-DIBROMO-7-HYDROXY-4-METHYL-2H-CHROMEN-2-ONE
- 19-(cyclopropylamino)-4,6,7,15-tetrahydro-5H-16,1-(azenometheno)-10,14-(metheno)pyrazolo[4,3-o][1,3,9]triazacyclohexadecin-8(9H)-one
- N,N\'-DIPHENYLPYRAZOLO[1,5-A][1,3,5]TRIAZINE-2,4-DIAMINE
- 4-(2-(1H-IMIDAZOL-4-YL)ETHYLAMINO)-2-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
- 2-(CYCLOHEXYLMETHYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
- 2-(4-CHLOROBENZYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
- 2-(4-ETHYLPIPERAZIN-1-YL)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
- N-(3-(8-CYANO-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZIN-2-YLAMINO)PHENYL)ACETAMIDE
- 2,3,7,8-tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione
- 5,6-dichloro-1-beta-D-ribofuranosyl-1H-benzimidazole
- 1,2,5,8-tetrahydroxyanthracene-9,10-dione
- Ellagic Acid
|
|
|
|
CSNK2A1 and FXR1 |
casein kinase 2, alpha 1 polypeptide |
fragile X mental retardation, autosomal homolog 1 |
- Mitotic Prometaphase
- Signal transduction by L1
- Axon guidance
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- L1CAM interactions
- Signaling by Wnt
- Cell Cycle, Mitotic
- M Phase
- WNT mediated activation of DVL
- TCF dependent signaling in response to WNT
- RNF mutants show enhanced WNT signaling and proliferation
- XAV939 inhibits tankyrase, stabilizing AXIN
- Signaling by WNT in cancer
- Condensation of Prometaphase Chromosomes
|
|
- (5-Oxo-5,6-Dihydro-Indolo[1,2-a]Quinazolin-7-Yl)-Acetic Acid
- 1,8-Di-Hydroxy-4-Nitro-Xanthen-9-One
- Resveratrol
- 1,8-Di-Hydroxy-4-Nitro-Anthraquinone
- Benzamidine
- 5,8-Di-Amino-1,4-Dihydroxy-Anthraquinone
- Phosphoaminophosphonic Acid-Adenylate Ester
- Tetrabromo-2-Benzotriazole
- DIMETHYL-(4,5,6,7-TETRABROMO-1H-BENZOIMIDAZOL-2-YL)-AMINE
- S-METHYL-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
- N1,N2-ETHYLENE-2-METHYLAMINO-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
- 3-METHYL-1,6,8-TRIHYDROXYANTHRAQUINONE
- 3,8-DIBROMO-7-HYDROXY-4-METHYL-2H-CHROMEN-2-ONE
- 19-(cyclopropylamino)-4,6,7,15-tetrahydro-5H-16,1-(azenometheno)-10,14-(metheno)pyrazolo[4,3-o][1,3,9]triazacyclohexadecin-8(9H)-one
- N,N\'-DIPHENYLPYRAZOLO[1,5-A][1,3,5]TRIAZINE-2,4-DIAMINE
- 4-(2-(1H-IMIDAZOL-4-YL)ETHYLAMINO)-2-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
- 2-(CYCLOHEXYLMETHYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
- 2-(4-CHLOROBENZYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
- 2-(4-ETHYLPIPERAZIN-1-YL)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
- N-(3-(8-CYANO-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZIN-2-YLAMINO)PHENYL)ACETAMIDE
- 2,3,7,8-tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione
- 5,6-dichloro-1-beta-D-ribofuranosyl-1H-benzimidazole
- 1,2,5,8-tetrahydroxyanthracene-9,10-dione
- Ellagic Acid
|
|
|
|
GABRR1 and MAPK1 |
gamma-aminobutyric acid (GABA) A receptor, rho 1 |
mitogen-activated protein kinase 1 |
- GABA receptor activation
- GABA A (rho) receptor activation
- Ion channel transport
- Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
- Ligand-gated ion channel transport
- Transmission across Chemical Synapses
|
- phospho-PLA2 pathway
- Ca-dependent events
- Signaling by FGFR in disease
- Cellular Senescence
- ERKs are inactivated
- CREB phosphorylation through the activation of Ras
- Signaling by EGFRvIII in Cancer
- Toll Like Receptor TLR1:TLR2 Cascade
- Toll Like Receptor 5 (TLR5) Cascade
- Gastrin-CREB signalling pathway via PKC and MAPK
- MyD88 dependent cascade initiated on endosome
- SOS-mediated signalling
- Fcgamma receptor (FCGR) dependent phagocytosis
- SHC-mediated signalling
- Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
- Regulation of actin dynamics for phagocytic cup formation
- TRIF-mediated TLR3/TLR4 signaling
- Senescence-Associated Secretory Phenotype (SASP)
- Signaling by VEGF
- Signalling to RAS
- Downstream signal transduction
- Toll Like Receptor 3 (TLR3) Cascade
- Interleukin-2 signaling
- Platelet activation, signaling and aggregation
- Frs2-mediated activation
- Transmission across Chemical Synapses
- Axon guidance
- IRS-mediated signalling
- L1CAM interactions
- Oncogene Induced Senescence
- VEGFA-VEGFR2 Pathway
- Activated TLR4 signalling
- VEGFR2 mediated cell proliferation
- GRB2 events in ERBB2 signaling
- RSK activation
- Activation of NMDA receptor upon glutamate binding and postsynaptic events
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- MyD88:Mal cascade initiated on plasma membrane
- NCAM signaling for neurite out-growth
- Signalling to p38 via RIT and RIN
- RAF/MAP kinase cascade
- Innate Immune System
- Signaling by Insulin receptor
- ERKs are inactivated
- Signal transduction by L1
- Insulin receptor signalling cascade
- PLC beta mediated events
- IRS-related events
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- SHC-related events
- G-protein mediated events
- Signaling by FGFR
- Thrombin signalling through proteinase activated receptors (PARs)
- ARMS-mediated activation
- Toll-Like Receptors Cascades
- Toll Like Receptor 10 (TLR10) Cascade
- Signal attenuation
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- ERK/MAPK targets
- MAPK targets/ Nuclear events mediated by MAP kinases
- Signaling by GPCR
- Mitotic Prophase
- Golgi Cisternae Pericentriolar Stack Reorganization
- FCERI mediated MAPK activation
- Signaling by SCF-KIT
- SHC1 events in ERBB2 signaling
- DAP12 signaling
- Toll Like Receptor 9 (TLR9) Cascade
- ERK/MAPK targets
- Negative regulation of FGFR signaling
- Signaling by PDGF
- DAP12 interactions
- Opioid Signalling
- SHC-related events triggered by IGF1R
- GRB2 events in EGFR signaling
- Signaling by ERBB4
- Toll Like Receptor 2 (TLR2) Cascade
- Signaling by ERBB2
- Signaling by EGFR
- Signaling by Interleukins
- SHC1 events in ERBB4 signaling
- Toll Like Receptor 4 (TLR4) Cascade
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- Signaling by Leptin
- Growth hormone receptor signaling
- Signalling to ERKs
- Prolonged ERK activation events
- ERK activation
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- IGF1R signaling cascade
- Recycling pathway of L1
- M Phase
- Toll Like Receptor TLR6:TLR2 Cascade
- IRS-related events triggered by IGF1R
- Activation of the AP-1 family of transcription factors
- MyD88 cascade initiated on plasma membrane
- ERK activation
- Downstream signaling of activated FGFR
- Advanced glycosylation endproduct receptor signaling
- Post NMDA receptor activation events
- Signalling by NGF
- SOS-mediated signalling
- MAP kinase activation in TLR cascade
- SHC-mediated signalling
- Cytokine Signaling in Immune system
- Cellular response to heat stress
- Regulation of HSF1-mediated heat shock response
- NGF signalling via TRKA from the plasma membrane
- MyD88-independent cascade
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Cell Cycle, Mitotic
- ERK2 activation
- SHC1 events in EGFR signaling
- FRS2-mediated cascade
- IRS-mediated signalling
- Oxidative Stress Induced Senescence
- ERK2 activation
- Nuclear Events (kinase and transcription factor activation)
|
- Lorazepam
- Temazepam
- Clobazam
- Alprazolam
- Picrotoxin
- Chlordiazepoxide
- Adinazolam
- Clorazepate
- Midazolam
- Flurazepam
- Halazepam
- Diazepam
- Oxazepam
- Triazolam
- Clonazepam
- Estazolam
- Bromazepam
- Clotiazepam
- Fludiazepam
- Prazepam
- Quazepam
- Cinolazepam
- Nitrazepam
|
- Isoproterenol
- Arsenic trioxide
- Olomoucine
- Phosphonothreonine
- Purvalanol
- SB220025
- N,N-DIMETHYL-4-(4-PHENYL-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
- N-BENZYL-4-[4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL]-1H-PYRROLE-2-CARBOXAMIDE
- (S)-N-(1-(3-CHLORO-4-FLUOROPHENYL)-2-HYDROXYETHYL)-4-(4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
- (3R,5Z,8S,9S,11E)-8,9,16-TRIHYDROXY-14-METHOXY-3-METHYL-3,4,9,10-TETRAHYDRO-1H-2-BENZOXACYCLOTETRADECINE-1,7(8H)-DIONE
- 5-(2-PHENYLPYRAZOLO[1,5-A]PYRIDIN-3-YL)-1H-PYRAZOLO[3,4-C]PYRIDAZIN-3-AMINE
- (1aR,8S,13S,14S,15aR)-5,13,14-trihydroxy-3-methoxy-8-methyl-8,9,13,14,15,15a-hexahydro-6H-oxireno[k][2]benzoxacyclotetradecine-6,12(1aH)-dione
- [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID
- 4-[5-(4-FLUORO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-3H-IMIDAZOL-4-YL]-PYRIDINE
|
|
|
GABRR1 and PRKCA |
gamma-aminobutyric acid (GABA) A receptor, rho 1 |
protein kinase C, alpha |
- GABA receptor activation
- GABA A (rho) receptor activation
- Ion channel transport
- Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
- Ligand-gated ion channel transport
- Transmission across Chemical Synapses
|
- Ca-dependent events
- Signaling by GPCR
- CaM pathway
- Signaling by FGFR in disease
- Phospholipase C-mediated cascade
- Integration of energy metabolism
- Mitotic Prophase
- Signaling by Wnt
- Signaling by EGFRvIII in Cancer
- PLCG1 events in ERBB2 signaling
- Signaling by SCF-KIT
- DAP12 signaling
- Regulation of KIT signaling
- Gastrin-CREB signalling pathway via PKC and MAPK
- Response to elevated platelet cytosolic Ca2+
- G alpha (z) signalling events
- Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
- Signaling by PDGF
- Calmodulin induced events
- DAP12 interactions
- Regulation of mRNA stability by proteins that bind AU-rich elements
- Opioid Signalling
- Diseases associated with visual transduction
- EGFR interacts with phospholipase C-gamma
- Signaling by ERBB2
- Signaling by EGFR
- Syndecan interactions
- GPCR downstream signaling
- Signaling by VEGF
- Calmodulin induced events
- Downstream signal transduction
- WNT5A-dependent internalization of FZD4
- Signaling by EGFR in Cancer
- Platelet activation, signaling and aggregation
- PCP/CE pathway
- Transmission across Chemical Synapses
- Trafficking of GluR2-containing AMPA receptors
- Nuclear Envelope Breakdown
- HuR stabilizes mRNA
- DAG and IP3 signaling
- M Phase
- VEGFA-VEGFR2 Pathway
- CaM pathway
- Inactivation, recovery and regulation of the phototransduction cascade
- EGFR Transactivation by Gastrin
- VEGFR2 mediated cell proliferation
- Downstream signaling of activated FGFR
- The phototransduction cascade
- Disinhibition of SNARE formation
- Innate Immune System
- Signalling by NGF
- PLC beta mediated events
- Regulation of insulin secretion
- Depolymerisation of the Nuclear Lamina
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- G-protein mediated events
- Non-integrin membrane-ECM interactions
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Trafficking of AMPA receptors
- Cell Cycle, Mitotic
- Signaling by FGFR
- beta-catenin independent WNT signaling
- Acetylcholine regulates insulin secretion
- Visual phototransduction
- Ca2+ pathway
- PLC-gamma1 signalling
- Glutamate Binding, Activation of AMPA Receptors and Synaptic Plasticity
|
- Lorazepam
- Temazepam
- Clobazam
- Alprazolam
- Picrotoxin
- Chlordiazepoxide
- Adinazolam
- Clorazepate
- Midazolam
- Flurazepam
- Halazepam
- Diazepam
- Oxazepam
- Triazolam
- Clonazepam
- Estazolam
- Bromazepam
- Clotiazepam
- Fludiazepam
- Prazepam
- Quazepam
- Cinolazepam
- Nitrazepam
|
- Phosphatidylserine
- Vitamin E
- Ingenol Mebutate
- Ellagic Acid
|
|
|
GABRR1 and SLC6A9 |
gamma-aminobutyric acid (GABA) A receptor, rho 1 |
solute carrier family 6 (neurotransmitter transporter, glycine), member 9 |
- GABA receptor activation
- GABA A (rho) receptor activation
- Ion channel transport
- Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
- Ligand-gated ion channel transport
- Transmission across Chemical Synapses
|
- Na+/Cl- dependent neurotransmitter transporters
- Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds
- SLC-mediated transmembrane transport
|
- Lorazepam
- Temazepam
- Clobazam
- Alprazolam
- Picrotoxin
- Chlordiazepoxide
- Adinazolam
- Clorazepate
- Midazolam
- Flurazepam
- Halazepam
- Diazepam
- Oxazepam
- Triazolam
- Clonazepam
- Estazolam
- Bromazepam
- Clotiazepam
- Fludiazepam
- Prazepam
- Quazepam
- Cinolazepam
- Nitrazepam
|
|
|
|
GABRR1 and P2RX2 |
gamma-aminobutyric acid (GABA) A receptor, rho 1 |
purinergic receptor P2X, ligand gated ion channel, 2 |
- GABA receptor activation
- GABA A (rho) receptor activation
- Ion channel transport
- Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
- Ligand-gated ion channel transport
- Transmission across Chemical Synapses
|
|
- Lorazepam
- Temazepam
- Clobazam
- Alprazolam
- Picrotoxin
- Chlordiazepoxide
- Adinazolam
- Clorazepate
- Midazolam
- Flurazepam
- Halazepam
- Diazepam
- Oxazepam
- Triazolam
- Clonazepam
- Estazolam
- Bromazepam
- Clotiazepam
- Fludiazepam
- Prazepam
- Quazepam
- Cinolazepam
- Nitrazepam
|
|
|
|
GABRR1 and GABRR2 |
gamma-aminobutyric acid (GABA) A receptor, rho 1 |
gamma-aminobutyric acid (GABA) A receptor, rho 2 |
- GABA receptor activation
- GABA A (rho) receptor activation
- Ion channel transport
- Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
- Ligand-gated ion channel transport
- Transmission across Chemical Synapses
|
- GABA receptor activation
- GABA A (rho) receptor activation
- Ion channel transport
- Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
- Ligand-gated ion channel transport
- Transmission across Chemical Synapses
|
- Lorazepam
- Temazepam
- Clobazam
- Alprazolam
- Picrotoxin
- Chlordiazepoxide
- Adinazolam
- Clorazepate
- Midazolam
- Flurazepam
- Halazepam
- Diazepam
- Oxazepam
- Triazolam
- Clonazepam
- Estazolam
- Bromazepam
- Clotiazepam
- Fludiazepam
- Prazepam
- Quazepam
- Cinolazepam
- Nitrazepam
|
|
|
|
GABRR1 and MAP1B |
gamma-aminobutyric acid (GABA) A receptor, rho 1 |
microtubule-associated protein 1B |
- GABA receptor activation
- GABA A (rho) receptor activation
- Ion channel transport
- Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
- Ligand-gated ion channel transport
- Transmission across Chemical Synapses
|
|
- Lorazepam
- Temazepam
- Clobazam
- Alprazolam
- Picrotoxin
- Chlordiazepoxide
- Adinazolam
- Clorazepate
- Midazolam
- Flurazepam
- Halazepam
- Diazepam
- Oxazepam
- Triazolam
- Clonazepam
- Estazolam
- Bromazepam
- Clotiazepam
- Fludiazepam
- Prazepam
- Quazepam
- Cinolazepam
- Nitrazepam
|
|
|
|
GABRR1 and SQSTM1 |
gamma-aminobutyric acid (GABA) A receptor, rho 1 |
sequestosome 1 |
- GABA receptor activation
- GABA A (rho) receptor activation
- Ion channel transport
- Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
- Ligand-gated ion channel transport
- Transmission across Chemical Synapses
|
- Signaling by Interleukins
- Signalling by NGF
- NF-kB is activated and signals survival
- p75NTR recruits signalling complexes
- Cell death signalling via NRAGE, NRIF and NADE
- NRIF signals cell death from the nucleus
- p75NTR signals via NF-kB
- Cytokine Signaling in Immune system
- Interleukin-1 signaling
- p75 NTR receptor-mediated signalling
|
- Lorazepam
- Temazepam
- Clobazam
- Alprazolam
- Picrotoxin
- Chlordiazepoxide
- Adinazolam
- Clorazepate
- Midazolam
- Flurazepam
- Halazepam
- Diazepam
- Oxazepam
- Triazolam
- Clonazepam
- Estazolam
- Bromazepam
- Clotiazepam
- Fludiazepam
- Prazepam
- Quazepam
- Cinolazepam
- Nitrazepam
|
|
|
|
GABRR1 and PRKG1 |
gamma-aminobutyric acid (GABA) A receptor, rho 1 |
protein kinase, cGMP-dependent, type I |
- GABA receptor activation
- GABA A (rho) receptor activation
- Ion channel transport
- Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
- Ligand-gated ion channel transport
- Transmission across Chemical Synapses
|
- Ca2+ pathway
- Signaling by Wnt
- beta-catenin independent WNT signaling
|
- Lorazepam
- Temazepam
- Clobazam
- Alprazolam
- Picrotoxin
- Chlordiazepoxide
- Adinazolam
- Clorazepate
- Midazolam
- Flurazepam
- Halazepam
- Diazepam
- Oxazepam
- Triazolam
- Clonazepam
- Estazolam
- Bromazepam
- Clotiazepam
- Fludiazepam
- Prazepam
- Quazepam
- Cinolazepam
- Nitrazepam
|
|
|
|